+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Marburgvirus Infections (Marburg Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 99 Pages
  • May 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5602708
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drugs In Development, 2022, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.

Report Highlights


The publisher's latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 25 and 8 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively.

Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of TablesList of FiguresIntroduction
Report Coverage
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Overview
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Assessment
Assesement by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Companies Involved in Therapeutics Development
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drug Profiles
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Product Development Milestones
Featured NewsAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer
List of Tables
  • Number of - Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), 2022
  • Number of - Products under Development by Companies, 2022
  • Number of - Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Companies, 2022 (Contd..1)
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by AIkido Pharma Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by AlphaVax Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Auro Vaccines LLC, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Collaborations Pharmaceuticals Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergex Vaccines Holding Ltd, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Fab’entech SA, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Flow Pharma Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Fox Chase Chemical Diversity Center Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Globavir Biosciences Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Greffex Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Helix Biogen Institute, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Integrated BioTherapeutics Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Intervir Therapeutics, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Mapp Biopharmaceutical Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Microbiotix Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Phoenix Biotechnology Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by ReVacc Biotech, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Rodos BioTarget GmbH, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Selva Therapeutics Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Soligenix Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by TFF Pharmaceuticals Inc, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, 2022
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, 2022 (Contd..1)
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products, 2022
List of Figures
  • Number of - Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), 2022
  • Number of - Products under Development by Companies, 2022
  • Number of - Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AIkido Pharma Inc
  • AlphaVax Inc
  • ANP Technologies Inc
  • Auro Vaccines LLC
  • BioCryst Pharmaceuticals Inc
  • Collaborations Pharmaceuticals Inc
  • Emergent BioSolutions Inc
  • Emergex Vaccines Holding Ltd
  • Fab’entech SA
  • Flow Pharma Inc
  • Fox